Bharat Parenterals’ subsidiary -- Innoxel Lifesciences has successfully cleared United States Food and Drug Administration (USFDA) inspection at its manufacturing facility in Vadodara, Gujarat.
The inspection was conducted from April 28, 2025 to May 2, 2025 and concluded with the issuance of a single minor observation under Form 483.
This outcome reflects Innoxel Lifesciences’ ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence across its manufacturing operations. The successful completion of this inspection further strengthens the company’s position in regulated markets and enhances its readiness to serve global customers with high-quality pharmaceutical products.
Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1226.10 |
| Cipla | 1228.55 |
| Zydus Lifesciences | 935.00 |
| Lupin | 2326.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: